In November 2023, we opened a new clinical unit in Ostrava (CZ). We have now received all necessary certificates for operation (including European GCP), and client audits are currently underway.

In addition, preparations for the first studies are progressing well, and we estimate that very first study will be initiated by the second quarter of this year.

To remind you of the festive atmosphere of the ribbon-cutting ceremony, we have prepared a video of the opening speech below.

The speech was held by Stephan Holl, CEO of Conscio Group, Roman Grunt, CEO of Quinta – Analytica, Jiří Juchelka, PI of Quinta – Analytica, and in the name of cooperation by Cyril Kučera, Deputy for Medical Care of the Ostrava City Hospital.

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

ALL POSTS